Angiodynamics, Inc. ( (ANGO) ) has released its Q3 earnings. Here is a breakdown of the information Angiodynamics, Inc. presented to its investors.
AngioDynamics, Inc. is a leading medical technology company specializing in vascular health, cancer treatment options, and enhancing patient quality of life through innovative devices and technologies. The company operates primarily in the healthcare sector, focusing on addressing unmet patient needs with its transformative solutions.
In its fiscal year 2025 third quarter financial results, AngioDynamics reported a notable increase in net sales and continued growth in its Med Tech segment. The company highlighted significant achievements, including FDA clearance for its NanoKnife System for prostate tissue ablation and the initiation of clinical trials to support its Auryon Atherectomy System.
Key financial metrics for the quarter included a 9.2% increase in net sales to $72.0 million, with Med Tech net sales growing by 22.2% to $31.3 million. The company achieved a GAAP gross margin of 54.0% and reported an adjusted EBITDA of $1.3 million. Despite a GAAP loss per share of $(0.11), the adjusted loss per share improved to $(0.08) compared to the previous year.
AngioDynamics’ strategic focus on expanding its Med Tech offerings has driven impressive growth, particularly in its Auryon, AngioVac, AlphaVac, and NanoKnife platforms. The company also secured a $25 million revolving line of credit from J.P. Morgan, enhancing its financial flexibility for future initiatives.
Looking ahead, AngioDynamics is optimistic about its growth prospects, with increased guidance for fiscal year 2025 across key metrics. The company is well-positioned to achieve its fiscal year 2026 profitability targets, supported by its strong portfolio and improved operational leverage.